API Product   :    Alcaftadine*
CEP   :    -
WCC   :    ?
Therapeutic Use    :    Systemic Antihistamines; Anti-Inflammatory And Anti-Rheumatic Products; Ophthalmologicals
Systemic Antihistamines; Anti-Inflammatory And Anti-Rheumatic Products; Ophthalmologicals
Originator   :    Vistakon Pharmaceuticals
CAS No.    :    147084-10-4
Trade Name.   :    LASTACAFT
Molecular Weight   :    307.40 g/ mol
307.40 g/ mol
Molecular Formula   :    C19H21N3O
Alcaftadine is used to prevent eye irritation brought on by allergic conjunctivitis. It is a H1 histamine receptor antagonist. It was approved by the U.S. Food and Drug Administration in 2010 under the trade name Lastacaft.
Alcaftadine is an antagonist at three of the histamine receptors (1, 2 and 4). The main indication for Alcaftadine is for prevention of allergic conjunctivitis. By blocking these three receptors, Alcaftadine has been shown to significantly reduce the effects of allergens. This effect on histamine receptors seems to show lower rates of itching, eosinophil recruitment and redness after exposure to an allergen. The effect of alcaftadine seemed to reduce the amount of eosinophil cells significantly as compared to olopatadine 0.1%. When animal models were used to test alcaftadine, alcaftadine 0.25% seemed to show superior results for decreasing E-cadherin expression as compared to placebo. The reduction of E-cadherin means decreased junctions which would lead to progression of allergic conjunctivitis.